Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer

Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed a pharmacogenomic analysis of MEKi-sensitive versus MEKi-resistant colorectal...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncogene
Prif Awduron: Wagner, Steve, Vlachogiannis, Georgios, De Haven Brandon, Alexis, Valenti, Melanie, Box, Gary, Jenkins, Liam, Mancusi, Caterina, Self, Annette, Manodoro, Floriana, Assiotis, Ioannis, Robinson, Penny, Chauhan, Ritika, Rust, Alistair G., Matthews, Nik, Eason, Kate, Khan, Khurum, Starling, Naureen, Cunningham, David, Sadanandam, Anguraj, Isacke, Clare M., Kirkin, Vladimir, Valeri, Nicola, Whittaker, Steven R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6462854/
https://ncbi.nlm.nih.gov/pubmed/30353166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0554-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg